AI-generated summary
The authors describe a planned open-label, single-arm study protocol testing photobiomodulation in patients with schizophrenia who have marked cognitive impairment. The primary outcome is safety and tolerability over 12 weeks of treatment and follow-up, with secondary measures of cognition, function and brain blood flow. No results are reported, as this is a protocol with 25 planned participants.
- Participants
- 25
- Who or what was studied
- Patients with schizophrenia and cognitive impairment, aged 18 to 70 years, planned enrollment of 25 (Japanese patients per the conclusion)
- Limits stated in the abstract
- This is a study protocol with no outcome data, and the open-label single-arm design has no control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on dovepress.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Intranasal photobiomodulation, Cerebral blood flow, Near-infrared, Primary outcome. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.